PNS occur in approx. 15% of malignant diseases, occur most frequently in association with small-cell lung carcinoma (SCLC), breast or ovarian carcinoma. Lambert-Eaton myasthenic syndrome (LEMS), which is the most frequent PNS and can be diagnosed by determining Purkinje cell antibodies, has the highest predictive value with respect to an underlying tumour (here SCLC). In most PNS, particularly in paraneoplastic limbic encephalitis (PLE), paraneoplastic cerebellar degeneration (PCD), paraneoplastic opsoclonus myoclonus ataxia (POMA), stiff-person syndrome (stiff-man syndrome) and retinopathy (subacute amaurosis), the detection of specific antibodies has a much higher predictive value with respect to the presence of a tumour than the clinical symptoms by themselves.
The EUROLINE Paraneoplastic Neurologic Syndromes 12 Ag is not suitable for the detection of antibodies against GAD65 in diabetes mellitus. A negative result in the EUROLINE does not exclude the presence of Anti-GAD65.
For the medical diagnosis, the clinical symptoms of the patient and, if available, further findings should always be taken into account alongside the serological result. A negative serological result does not exclude the presence of a disease because this test can determine autoantibodies of the immunoglobulin class IgG against only 12 different antigens. Not all of the target antigens of autoantibodies associated with paraneoplastic syndromes have yet been identified, purified and sufficiently validated.